AbbVie Inc (ABBV)vsGinkgo Bioworks Holdings (DNA)
ABBV
AbbVie Inc
$211.32
-2.23%
HEALTHCARE · Cap: $360.63B
DNA
Ginkgo Bioworks Holdings
$9.70
+14.66%
HEALTHCARE · Cap: $551.05M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 35844% more annual revenue ($61.16B vs $170.16M). ABBV leads profitability with a 6.9% profit margin vs -183.8%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
DNA
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.3%
Fair Value
$163.59
Current Price
$211.32
$47.73 premium
Margin of Safety
+33.4%
Fair Value
$14.03
Current Price
$9.70
$4.33 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -51.1% — below average capital efficiency
Revenue declined 23.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while DNA is a turnaround play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.57 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100). DNA offers better value entry with a 33.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a frontrunner in the synthetic biology industry, leveraging cutting-edge genetic engineering techniques to develop tailored bioengineered organisms for diverse applications in pharmaceuticals, agriculture, and industrial biotechnology. The company’s innovative platform enhances cellular design for manufacturing, optimizing product development and streamlining production processes. With a strong focus on solving critical global challenges, including climate change and food security, Ginkgo is well-positioned to influence multiple sectors while fostering sustainable advancements in biotechnology. As the industry evolves, Ginkgo's commitment to bio-based solutions positions it for significant growth and impact.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?